{"id":"W2560387080","doi":"10.1182/blood.v118.21.1986.1986","title":"A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Nilotinib; Medicine; Prednisone; Adverse effect; Refractory (planetary science); Internal medicine; Tyrosine-kinase inhibitor; Pharmacology; Dosing; Imatinib; Corticosteroid; Gastroenterology; Urology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001137369,0.001156605,0.001469886,0.0005126286,0.0004393876,0.0009211988,0.0005649967,0.0007411675,0.002770777],"category_scores_gemma":[0.0006886914,0.0004544279,0.0008079889,0.0003403495,0.0008615288,0.0007090336,0.0002736395,0.002397773,0.0005942865],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007392717,"about_ca_system_score_gemma":0.0009917784,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005867833,"about_ca_topic_score_gemma":0.00178939,"domain_scores_codex":[0.9996238,0.0001623328,0.00001985862,0.00005956173,0.00004651297,0.00008787372],"domain_scores_gemma":[0.9994313,0.00008984938,0.00009058475,0.00004796219,0.00004399147,0.0002962824],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6453322,0.1516974,0.007714096,0.0008507992,0.001110205,0.0005491208,0.0004787318,0.003379166,0.08666442,0.0005273073,0.004137906,0.09755864],"study_design_scores_gemma":[0.4391005,0.5436922,0.009811653,0.00002411108,0.0001777927,0.0002304533,0.00007158049,0.001328543,0.003193127,0.0002810375,0.002059223,0.00002973397],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995513,0.0009718682,0.0003864523,0.0002007284,0.00006944546,0.001330075,0.0004803976,0.00005238675,0.0009956353],"genre_scores_gemma":[0.9945246,0.0006835387,0.0007742174,0.0004964467,0.00007100729,0.0009776275,0.0008670393,0.00001556311,0.001589986],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002770777,"threshold_uncertainty_score":0.009269178,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08625308435952153,"score_gpt":0.3471174880040857,"score_spread":0.2608644036445642,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}